Determination of Oral Bioavailability of Fusaric Acid in Male Sprague-Dawley Rats by Brendan C. Stack et al.
ORIGINAL RESEARCH ARTICLE
Determination of Oral Bioavailability of Fusaric Acid in Male
Sprague-Dawley Rats
Brendan C. Stack Jr. • John Ye • Rebecca Willis •
Martha Hubbard • Howard P. Hendrickson
Published online: 6 June 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Head and neck squamous cell cancer accounts
for 3 % of new cancer cases and 2 % of cancer mortality
annually in the United States. Current treatment options for
most head and neck cancers continue to be surgical exci-
sion with or without radiation, radiation alone, or chemo-
therapy with radiation depending on location, stage of
disease, and patient preference. Fusaric acid (FA) is a novel
compound from a novel class of nicotinic acid derivatives
that have activity against head and neck squamous cell
carcinoma (HNSCC). Although its exact mechanism is still
unknown, FA is thought to be active by increasing damage
to DNA and preventing its synthesis and repair. The novel
mechanism of FA provides an alternative to present ther-
apies, as a single agent whether given parenterally or
orally. It has synergy with conventional agents taxol, car-
boplatin, and erlotinib. In order to determine if FA has
reasonable oral bioavailability, we have determined the
pharmacokinetics of FA in male Sprague Dawley rats
following administration by gavage and by intravenous
injection. The bioavailability of FA was sufficient (58 %)
to suggest that FA may be viable as an orally administered
medication. Despite the encouraging bioavailability of FA,
the intravenous (IV) pharmacokinetics suggested non-lin-
ear behavior within the IV dose range of 10, 25, and
75 mg/kg. These results demonstrate that further
pharmacokinetic and toxicity studies in larger animals such
as dogs and non-human primates are warranted.
1 Introduction
Head and neck squamous cell cancer accounts for 3 % of
new cancer cases and 2 % of cancer mortality annually in
the United States [1]. Globally, head and neck squamous
cell carcinoma (HNSCC) affects over 500,000 patients
each year, making it the sixth in incidence and the seventh
in mortality in the world [2].
Current treatment options for most head and neck can-
cers continue to be surgical excision with or without
radiation, radiation alone, or chemotherapy with radiation
depending on location, stage of disease, and patient pref-
erence. While advances have been made in the delivery of
treatment, little change has been seen in the overall sur-
vival of head and neck cancer patients for decades [2].
Currently, no effective single agent chemotherapy treat-
ment regimen is available for head and neck cancer.
Additionally, oral chemotherapy is currently limited in its
use, usually as second- or third-line therapy or in a clinical
trial.
Fusaric acid (FA) is a novel compound from a novel
class of nicotinic acid derivatives, which have activity
against HNSCC. FA is produced by Fusarium species as a
mycotoxin [3]. Mycotoxins are highly toxic compounds
produced by fungi usually for the purposes of self-defense
or to dissolve cell membranes as part of their fungal
pathogenicity. Also known as 5-butlypicolinic acid, FA has
been reported to have a number of pharmacologic effects in
mammals including cardiovascular [4] and potential
adverse neurological effects [5]. The therapeutic effects
were observed at doses in the range of 10–30 mg/kg, while
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adverse effects were observed at a significantly higher dose
of 100 mg/kg [5].
Although its exact mechanism is still unknown, FA is
thought to be active by increasing damage to DNA and
preventing its synthesis and repair [6]. This may be in part
from chelation of divalent cations from catalytic DNA-
associated metalloproteins. Chelation as a mechanism has
been observed as the effect of other compounds upon
cancer. Sorenson and Wanglia [7] reported tetrathiomo-
lybdate chelates copper from proangiogenic molecules,
thereby causing a reversible growth arrest in squamous cell
carcinoma (SCC) in vitro and caused by decreased vascular
proliferation within the tumor bed. Conversely, chelation
has also been shown to activate proangiogenic genes
including vascular endothelial growth factor (VEGF) in
other models [8]. We have also observed significant cyto-
kine changes induced by FA and this may also explain the
cytostatic or cytocidal effects of FA [9].
FA has demonstrated anti-tumorigenic activity in non-
epidermoid carcinomas such as adenocarcinoma and
hepatocellular carcinoma [6, 10]. Our data demonstrate a
suppressive effect of FA upon two HNSCC (epidermoid)
lines (Hep-2 and UMSCC-1) in vitro [11]. Additionally, in
a docetaxel-resistant head and neck cancer cell line, FA
demonstrates a concentration-driven suppression of cell
growth [9].
The novel mechanism of FA provides an alternative to
present therapies [9] as a single agent whether given par-
enterally or orally. It has synergy with conventional agents
taxol, carboplatin, and erlotinib. It has shown effect upon
resistant cell lines in culture and in laboratory animals,
which may offer the possibility of its use in the setting of
treatment failure. Preliminary data show no evidence of
toxicity at therapeutic doses. The efficacy and potency of
orally administered FA suggests that it would be practical
as an ambulatory oral therapy [12, 13].
Potential applications of FA might include use as a
second-line drug for patients who have failed first-line
therapy, inhibition of growth of known metastatic carci-
noma (chronic therapy), prophylactic therapy against
recurrent or second primary disease given to high-risk
patients (patients with the previous diagnosis of HNSCC),
or as a first-line agent given in combination with another
chemotherapy using an alternative mechanism of action.
We have accumulated substantial animal evidence to
pursue phase I trials of FA in humans. These data suggest
that an oral dose of 25 mg/kg per day is efficacious toward
HNSCC in mice [11–13]. Prior to phase I clinical trials, the
oral bioavailability of FA in an animal model must be
evaluated to guide a phase I experimental design. In the
study described here, the oral bioavailability was deter-
mined from the ratio of the area under the serum concen-
tration–time curve following oral administration (AUCPO)
to the area under the serum concentration–time curve fol-
lowing intravenous administration (AUCIV). The bio-
availability was calculated from each animal since each
received an IV dose and an oral (PO) dose. Additional
studies will determine the linearity of the pharmacokinetic
parameters at the different IV doses of FA.
2 Materials and Methods
2.1 Chemicals and Supplies
FA from Gibberella fujikuroi was purchased from Sigma-
Aldrich (St. Louis, MO). The liquid chromatography-mass
spectrometry (LC-MS) internal standard, citrulline (5-13C,
99 %; 4,4,5,5-D4, 95 %), was purchased from Cambridge
Isotope Laboratories (Tewksbury, MA). FA was prepared
for dosing by dissolving an appropriate amount of com-
pound in preservative-free sterile saline (University hos-
pital supply). Formic acid and trifluoroacetic acid were LC-
MS grade and purchased from Thermo Fisher Scientific
(Pittsburgh, PA). Water, acetonitrile, and methanol were
Optima LC-MS grade and obtained from Thermo Fisher.
Control plasma was obtained from Innovative Research
(Novi, MI).
2.2 Pharmacokinetic Studies
The pharmacokinetics of FA administered orally and
intravenously were characterized. Sprague-Dawley rats
surgically implanted with catheters in the left and right
jugular veins (JV) were used for all studies. All surgical
procedures were performed by the vendor (Charles River
Laboratories) prior to shipment. Animals were placed in
separate cages and allowed to free feed for 3 days.
On the first experimental day, a 250-lL blood sample
was removed from the right JV catheter (JVC) as control.
Each animal was administered 25 mg/kg IV FA in saline
vehicle through the left JVC in a volume of 1 mL/kg.
Blood samples (200 lL) were removed from the right JVC
at 5, 10, 30, 50, 60 minutes, and 2, 4, 6, and 8 hours fol-
lowing drug administration. Prior to the removal of each
experimental blood sample, the catheter was cleared of
vehicle by removing approximately 150 lL. This dead
volume was replaced after collecting the experimental
sample. Saline solution (100 lL) was used to flush the
catheter after each draw. Animals were fasted beginning at
approximately 5 pm on the day prior to oral administration
of FA. On the following day, the animal was administered
25 mg/kg PO FA in saline vehicle by gavage (4 mm tip
stainless steel blunt needle). Experimental samples were
collected as before at 5, 10, 30, 50, 60 minutes, and 2, 4, 6,
and 8 hours. All animal experiments were approved and
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performed in compliance with the University of Arkansas
for Medical Sciences Institutional Animal Care and Use
Committee guidelines.
Blood samples were allowed to clot for at least
20 minutes and then centrifuged (12,0009g) for 10 min-
utes. The serum from each sample was promptly removed
and stored at -20 C until analysis by liquid chromatog-
raphy with mass spectrometric detection. AUC values and
elimination half-life values were determined using an
Excel-based non-compartmental analysis program (PK
Solutions 2.0, Summit Research Services, Montrose, CO).
24-hour urine samples were collected by placing rats in
metabolism cages (Nalgene Model 655-0100, Rochester,
NY) following administration of either 10 mg/kg (n = 3)
or 25 mg/kg (n = 7) FA (IV). Animals were allowed free
access to food and water while housed in metabolism
cages.
2.3 Sample Preparation and LC-MS
Protein precipitation of serum samples (10 lL) and serum
standards (10 lL) was performed in 96-well Strata Impact
2 ml filtration plates (Phenomenex, Torrance, CA). To
each well was added 490 lL acetonitrile:water:formic acid
(85:14.8:0.2 v/v) containing citrulline?5 stable isotope as
internal standard (IS). This was followed by the addition of
10 lL of serum. After mixing gently, the plate was cov-
ered, allowed to stand for 5 minutes, and the filtrate was
collected under vacuum. The 96-well collection plate was
loaded into the Acquity (Waters, Corp., Milford, MA)
sample manager and the sample (3 lL) was injected onto
the analytical column.
The high-performance liquid chromatography (HPLC)
system was a Waters Acquity series (Waters) equipped
with a sample manager, binary pump, in-line degasser, and
a column thermostat. The mass spectrometer was a Quattro
Premier equipped with an electrospray ionization probe
(Waters). Analytical separation was optimally achieved on
a Phenomenex 1.7 lm KinetexDiol analytical column
[50 9 2.1 mm (i.d.)].
FA was separated using a linear binary gradient in
hydrophilic interaction liquid chromatography (HILIC)
mode (Mobile phase A: acetonitrile containing 0.1 % for-
mic acid, 0.2 % acetic acid and 0.005 % trifluoroacetic
acid; Mobile phase B: water containing 0.1 % formic acid,
0.2 % acetic acid and 0.005 % trifluoroacetic acid). Ini-
tially the flow rate was 0.4 mL/min. The gradient was
increased from 10 to 80 % B in the first 2.3 minutes and
held at 80 % B for 0.2 minutes while the flow rate was
increased to 0.6 mL/min. The gradient was returned to
10 % B over 1 minute. The total run time was 5.0 minutes.
Detection of 5-13C, 4,4,5,5-2H-citrulline (citrulline?5) and
FA was achieved following electrospray ionization
interfaced to a Quattro Premier triple quadrupole mass
spectrometer (Waters). Positive ions for FA and citrul-
line?5 were generated using a cone voltage of 22 and
18 V, respectively. Product ions were generated using
argon collision-induced disassociation at collision energy
of 10 eV while maintaining a collision cell pressure of
2.8 9 10-3 torr. Detection was achieved in the multiple-
reaction-monitoring (MRM) mode using the precur-
sor ? product ions, m/z180.2 ? 162 and 181 ? 164, for
FA and citrulline?5, respectively. Citrulline?5 (5 lM)
served as the internal standard. Matrix ion effects were
evaluated using the post-column infusion technique, which
has been described elsewhere [14]. Separate citrulline?5
(10 lM) and FA (10 lM) solutions were prepared in ace-
tonitrile containing 20 % water. These were infused in
separate experiments at a rate of 10 lL/min and mixed
with column eluent during an injection of extracted serum.
Analytical recovery and inter-day precision were eval-
uated using quality control standards prepared from a
separated stock solution of FA. Quality control samples
were prepared in FA-free mouse serum (Innovative
Research, Novi, MI) at 10, 100, and 3,000 lM FA. Quality
control standards were taken through seven freeze-thaw
cycles by removing standards from -20 C, removing a
10 ll aliquot for analysis, thawing at room temperature,
and returning the standards to -20 C. At least 1 day
elapsed between freeze-thaw cycles with a seven-cycle
freeze-thaw study taking place over a period of 30 days.
3 Results
3.1 Liquid Chromatography-Tandem Mass
Spectrometry (LC-MS/MS)
A representative chromatogram of an extracted serum FA
standard (30 lM) containing internal standard is shown in
Fig. 1. The lower limit of quantitation (LLOQ) was 10 lM
(from 10 ll sample) and the upper limit of quantitation was
3,000 lM. The LLOQ was defined as the lowest calibration
standard that resulted in an analytical recovery of
80–120 % and a reproducibility of ±20 %. The analytical
recovery for FA was 116 ± 14 % at 10 lM. Inter-day
precision and accuracy results are shown in Table 1.
Quality control standards were quantified on seven non-
consecutive days covering a period of 30 days. Matrix ion
suppression was not observed for either the internal stan-
dard or FA. Increases in the MRM trace (1.80–2.3 min) for
FA (m/z 180.2 ? 162) while infusing 10 lM FA during an
injection of extracted serum were associated with changes
in the gradient and not unique to the extracted serum. The
MRM trace for citrulline?5 was stable through the chro-
matographic run.
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The chromatographic peak shape for the internal stan-
dard (k = 0.75) was not optimized and peak splitting was
observed. Since peak splitting was not observed for FA
(k = 6.3), and the precision for the integrated peak area for
the internal standard was not compromised due to volume
overload, it was reasoned that the poor peak shape asso-
ciated with the internal standard was not detrimental to the
quantitation of FA.
3.2 Bioavailability
FA was administered to nine animals for bioavailability
studies, with each animal receiving an IV and PO dose at
25 mg/kg. Toxicity (i.e., chromodacyrea) was not observed
in any of these animals. After completion of a study, each
animal was sacrificed in a CO2 chamber. Complete studies
(8 h) were completed on only five animals. The initial
study was designed anticipating an elimination half-life of
about 30 minutes. During the course of these preliminary
studies, the analytical sensitivity for the quantitation of FA
was improved and blood samples were collected for
8 hours instead of 2 hours as originally planned. The
results reported here are from rats in which blood samples
were collected for 8 hours. Rat 3 was delivered with a non-
patent catheter and could not be used for these studies. In
all animals, the FA serum concentration fell below the
lower limit of quantitation (i.e., 10 lM) within 4 hours of
FA administration.
Serum concentration-time profiles following IV and PO
administration of 25 mg/kg FA are shown in Fig. 2 and the
corresponding pharmacokinetic parameters derived from
these data are provided in Table 2. The average oral bio-
availability for FA was quite favorable at 58 %. Curiously,
there was a significant difference in the elimination half-
life when comparing IV- (33 ± 6 min) with PO-
(24 ± 4 min) administered FA (p = 0.01). For well
behaved compounds, the elimination half-life should be
independent of the route of administration, but it is possible
that an insufficient number of blood samples were collected
beyond the adsorption/distribution phase of FA disposition.
This would effectively shorten the elimination half-life
obtained following administration by gavage. Another
explanation for the apparent effect of route of administra-
tion on elimination half-life is that either the volume of
distribution or the clearance is affected on the route of
administration.
Careful consideration of the apparent volume of distri-
bution and clearance suggests that volume of distribution is
affected to a greater extent by oral administration than for
clearance. The apparent volume of distribution for FA was
significantly higher (p = 0.002) following IV administra-
tion (251 ± 28 ml) versus oral administration
(182 ± 27 ml). Clearance values for the two routes of
administration were not significantly different (p = 0.8).
Very little of the FA administered by IV was excreted
unchanged in the urine. Following IV administration of 10
or 25 mg/kg, 1.7 and 2.0 % FA was excreted in urine
(24 h).
3.3 IV Dose Effects
FA was well tolerated in rats at IV doses of 10, 25, and
75 mg/kg with no adverse effects observed. The pharma-
cokinetics were not well behaved and the results, which are
summarized in Tables 2 and 3, suggest non-linear phar-
macokinetic behavior for FA over the dose range studied.
While there was larger than expected variation in the
clearance at 10 mg/kg (47 ± 34 mL/h), there was no sig-
nificant difference in the clearance at any of the doses
studied. The clearance at 25 and 75 mg/kg was 81 ± 14
and 40 ± 5 mL/h, respectively. Though statistical differ-
ences in clearance at these doses were not observed, the
data are strongly suggestive of non-linear pharmacokinet-
ics. The effects of dose on maximum concentration (Cmax)
and time to Cmax (Tmax) are clearly important since these
parameters are directly related to the rate and extent of






Fig. 1 Liquid chromatography-tandem mass spectrometry (LC-MS/
MS) chromatogram of extracted serum sample spiked with 30 lM
fusaric acid and 30 lM citrulline?5 (internal standard)







10 10.1 3.6 36 101
100 109.4 20.2 18 109
3000 2799.9 421.2 15 93
SD Standard deviation (n = 7). CV Coefficient of varia-
tion = 100*(SD/Predicted Conc.)
a Values are the mean
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absorption. Since these dose effects were not determined
here, these studies should be undertaken in the future.
4 Discussion
Few descriptions of the pharmacokinetics of FA can be
found in the literature. Matsuzaki et al. reported the dis-
position of FA following an oral dose of 20 mg/kg in the
rat [15]. In this study, the acyl carbon was labeled with the
radioisotope and total radioactivity in various tissues was
determined. Peak radioactivity was achieved in 30 minutes
with a calculated FA concentration of 42 ± 7.4 lg/mL.
These results are in good agreement with the results
reported here and shown in Table 2. A concentration of
290 lM is equivalent to 52 ± 11 lg/mL FA. A simple
unpaired t-test indicates that there is no significant different
in the Cmax reported herein and that reported by Matsuzaki
et al. [15] (p = 0.24, alpha 0.05, 95 % clearance). In the
present study, little of the FA was excreted unchanged
(B2 %) in the urine. Matsuzaki et al. reported 87 % of the
total radioactivity administered was recovered in urine
(24 h). This apparent difference can be explained in light
of the fact that Matsuzaki et al. used FA labeled at the acyl
carbon. Previous studies have shown that this acyl carbon
is retained in FA metabolites [16], so it is not surprising
that 87 % of the radioactivity was excreted in the earlier
study since much of this radioactivity would be associated
with metabolites. Umezawa has also shown that \5 % FA
is excreted unchanged in the urine [16].
Linear pharmacokinetics were not observed for the IV
doses administered in this study. Non-linear pharmacoki-
netic parameters suggest that metabolic enzymes, trans-
porters, and protein-FA interactions are saturated at the
concentrations produced within the dose range of
10–75 mg/kg. These are the first and only studies of this
type conducted in any species. Earlier reports on the acute
toxicity observed mild gastrointestinal hemorrhage and
erosion in Wistar male rats following administration of
32 mg/kg FA by gavage [17]. This dose is very close to the
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Serum Concentration-time profiles for Fusaric Acid following administration of 25 mg/kg to Sprague 
Dawley Rats
Fig. 2 Serum concentration-time profile for fusaric acid following
administration of 25 mg/kg fusaric acid. Fusaric acid was adminis-
tered by either the intravenous (IV) (closed circles) or oral (PO) (open
circles) route. A 1-week wash-out period was allowed between IV
and PO administrations. Fusaric acid concentrations were determined
by hydrophilic interaction liquid chromatography (HILIC)-tandem
mass spectrometry (MS/MS) following protein precipitation and
filtration of serum samples (10 ll)
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25 mg/kg dose administered in the present study and
therefore some of the same gastrointestinal effects might be
expected here as well. Since necropsies were not performed
in the current study, the degree of intestinal damage was
not assessed.
The bioavailability of FA (58 %), while not optimal,
demonstrates that further pharmacokinetic and toxicity
studies in larger animals such as dogs and non-human
primates are warranted. The effects of dose on the IV
pharmacokinetic parameters raise some questions on the
ability to safely scale the dosage from rat to human use.
Repeating these studies in higher order animal species,
such as non-human primates, should in part answer ques-
tions of dose scalability of FA use in humans.
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